Fechner G A, Michel J, Sturm R A, Jacobs J J, Parsons P G
Pharmacy Department, University of Queensland, Australia.
Biochem Pharmacol. 1994 Jul 5;48(1):121-30. doi: 10.1016/0006-2952(94)90231-3.
Two groups of S-[2-(N,N-dialkylamino)ethyl]isothiourea derivates which depigmented melanoma cells either with inhibition of tyrosinase (group 1, R = methyl, isopropyl) or without inhibition of tyrosinase (group 2, R = benzyl, phenyl) were studied. Treatment of human melanoma cells with non-lethal doses of group 1 drugs led to a reduction in the levels of mRNA for the pigmentation genes tyrosinase, tyrosinase-related protein-1 and Pmel 17. The group 1 drug S-[2-N,N-diisopropylamino)ethyl[isothiourea] (DINOR) (R = isopropyl) produced only moderate inhibition of DNA, RNA and protein synthesis in three cell lines during the first 24 hr of treatment, and there was no correlation between the extent of inhibition and long-term toxicity. A group 2 drug (R = benzyl) rapidly inhibited DNA synthesis in an amelanotic melanoma cell line (MM96E) sensitive to killing by the drug; association of the latter with inhibition of RNA or protein synthesis was less clear. MM96E cells were also sensitive to killing by reactive oxygen species. In pigmented melanoma cells (MM418), incorporation of [125I]thiouracil, a false precursor of melanin, increased during the first 24 hr of treatment with DINOR whereas a group 2 drug (R = phenyl) inhibited incorporation of [125I]thiouracil. Cells depigmented by treatment with drugs from either group suffered the same amount of DNA damage as pigmented cells after UVB irradiation, as judged by inhibition of DNA synthesis, but did not recover as well as pigmented cells, whether or not drug was present during recovery. The results suggested that (1) group 1 agents down-regulated message for several pigmentation genes, possibly at the transcriptional level; (2) the toxicity of group 2 drugs was related to reactive oxygen species; and (3) melanin protected cells from UVB by enhancing cellular recovery.
研究了两组S-[2-(N,N-二烷基氨基)乙基]异硫脲衍生物,其中一组(第1组,R = 甲基、异丙基)通过抑制酪氨酸酶使黑色素瘤细胞色素脱失,另一组(第2组,R = 苄基、苯基)则不抑制酪氨酸酶。用非致死剂量的第1组药物处理人黑色素瘤细胞,导致色素沉着基因酪氨酸酶、酪氨酸酶相关蛋白-1和Pmel 17的mRNA水平降低。第1组药物S-[2-N,N-二异丙基氨基)乙基]异硫脲(DINOR)(R = 异丙基)在处理的前24小时内仅对三种细胞系的DNA、RNA和蛋白质合成产生中度抑制,且抑制程度与长期毒性之间没有相关性。第2组药物(R = 苄基)能迅速抑制对该药物杀伤敏感的无黑色素黑色素瘤细胞系(MM96E)中的DNA合成;其与RNA或蛋白质合成抑制之间的关联不太明显。MM96E细胞对活性氧的杀伤也很敏感。在用DINOR处理的前24小时内,色素沉着的黑色素瘤细胞(MM418)中黑色素的假前体[125I]硫脲的掺入增加,而第2组药物(R = 苯基)则抑制[125I]硫脲的掺入。用两组中任一组药物处理后色素脱失的细胞,经紫外线B(UVB)照射后,与色素沉着细胞相比,DNA合成受抑制程度相同,表明其DNA损伤程度相同,但无论恢复过程中是否存在药物,其恢复情况都不如色素沉着细胞。结果表明:(1)第1组药物可能在转录水平下调几种色素沉着基因的信息;(2)第2组药物的毒性与活性氧有关;(3)黑色素通过增强细胞恢复来保护细胞免受UVB损伤。